文献速递肿瘤 PET/CT

新型EphA2靶向PET示踪剂从临床前到胰腺癌首次人体研究

Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-03

本研究开发了三种68Ga标记的EphA2靶向示踪剂,在体外和荷瘤小鼠中评估稳定性、亲和力与药代动力学,并选择68Ga-FZEAR-2在2例胰腺导管腺癌患者中进行首次人体PET/CT。结果显示该示踪剂可清晰显示原发和转移病灶且无不良反应,免疫组化证实高摄取病灶表达EphA2。

要点

  • 68Ga-FZEAR-2在临床前显示高肿瘤摄取、低非靶摄取和良好安全性。
  • 首次人体PET/CT(n=2)中68Ga-FZEAR-2清晰显示原发和转移灶且无不良反应。
  • 免疫组化证实高摄取病灶表达EphA2,提示可无创可视化EphA2表达。

核心结论

  • 成功开发并评估了一系列68Ga标记的EphA2靶向示踪剂。
  • 先导候选68Ga-FZEAR-2显示有前景的靶向特异性和良好药代动力学。
  • 初步研究提示68Ga-FZEAR-2可在胰腺导管腺癌患者中无创可视化EphA2表达。

研究设计与样本

  • 合成68Ga-FZEAR-1、68Ga-FZEAR-2和68Ga-FZEAR-3,并在体外和体内评估稳定性、亲和力及药代动力学。
  • 在EphA2阳性和EphA2阴性肿瘤异种移植模型中进行进一步生物学评价。
  • 随后在2例胰腺导管腺癌患者中对先导候选68Ga-FZEAR-2进行首次人体PET/CT初步研究。

主要发现

  • 三种68Ga示踪剂放射化学纯度均>99%,对EphA2显示高稳定性和纳摩尔级亲和力。
  • 细胞摄取与EphA2表达一致,阻断实验证实特异性。
  • 体内所有示踪剂均显示高肿瘤蓄积和低非靶摄取。
  • 68Ga-FZEAR-2显示良好的肿瘤靶向能力、药代动力学和安全性。
  • 初步临床研究(n=2)中68Ga-FZEAR-2 PET/CT清晰显示原发和转移病灶且无不良反应。

关键数值与推荐

  • 三种68Ga示踪剂放射化学纯度>99%。
  • 示踪剂对EphA2显示纳摩尔级亲和力。
  • 初步临床研究样本量为2例胰腺导管腺癌患者。

临床怎么用

  • 68Ga-FZEAR-2 PET/CT有望用于胰腺导管腺癌的EphA2表达无创可视化。
  • 该示踪剂可能作为胰腺导管腺癌精准诊断的工具。

局限性

  • 首次人体研究仅为初步探索,样本量仅2例胰腺导管腺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ephrin type-A receptor 2 (EphA2) is a promising target in pancreatic ductal adenocarcinoma (PDAC). However, the clinical potential of targeting EphA2 requires further imaging evaluation. This study developed and preliminarily evaluated a novel 68Ga-labeled radiotracer for PET imaging of EphA2 expression in PDAC patients. METHODS: 68Ga-FZEAR-1, 68Ga-FZEAR-2, and 68Ga-FZEAR-3 were synthesized, and their stability, affinity, pharmacokinetics were evaluated in vitro and in vivo. Further biological evaluation was performed in EphA2-positive and EphA2-negative tumor xenografts. A pilot first-in-human PET/CT study of the lead candidate, 68Ga-FZEAR-2, was subsequently conducted in two PDAC patients. RESULTS: The three 68Ga-radiotracers were synthesized with high radiochemical purity (> 99%) and demonstrated high stability and nanomolar affinity for EphA2. Cellular uptake was consistent with EphA2 expression and blocking assays confirmed specificity. In vivo, all tracers exhibited high tumor accumulation with low off-target uptake. 68Ga-FZEAR-2 showed favorable tumor-targeting ability, pharmacokinetics, and safety profile. In the pilot clinical study (n = 2), 68Ga-FZEAR-2 PET/CT visualized primary and metastatic lesions clearly without adverse effects. Immunohistochemical analysis confirmed EphA2 expression in lesions exhibiting high tracer uptake. CONCLUSION: A series of 68Ga-labeled tracers for EphA2 imaging was successfully developed and evaluated. The lead candidate, 68Ga-FZEAR-2, showed promising targeting specificity and favorable pharmacokinetics. A pilot study indicated that 68Ga-FZEAR-2 provided preliminary evidence of noninvasive visualization of EphA2 expression in PDAC patients, thereby suggesting its potential as a tool for precision diagnosis in PDAC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu X, Sun L, Lei J, et al. Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42234007. doi:10.1007/s00259-026-07966-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。